Inicio>>Signaling Pathways>> Others>>SCH 32615

SCH 32615

Catalog No.GC61457

SCH 32615 es un inhibidor de la encefalinasa (las enzimas responsables de la degradaciÓn de las encefalinas endÓgenas).

Products are for research use only. Not for human use. We do not sell to patients.

SCH 32615 Chemical Structure

Cas No.: 83861-02-3

Tamaño Precio Disponibilidad Cantidad
5 mg
93,00 $
Disponible
10 mg
158,00 $
Disponible
25 mg
324,00 $
Disponible
50 mg
510,00 $
Disponible
100 mg
881,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

SCH 32615 is an enkephalinase (the enzymes responsible for the degradation of endogenous enkephalins) inhibitor. SCH 32615 can enhance surgery- and pregnancy-induced analgesia in mice[1][2].

SCH 32615 blocks the degradation of Met5-enkephalin by isolated enkephalinase, with the Ki of 19.5 nM[3].

SCH 32615 (150 mg/kg; s.c.) enhances surgery activated endogenous analgesia in mice[1].

[1]. Jayaram A, et, al. An enkephalinase inhibitor, SCH 32615, augments analgesia induced by surgery in mice. Anesthesiology. 1995 May;82(5):1283-7. [2]. Jayaram A, et, al. SCH 32615, an enkephalinase inhibitor, enhances pregnancy-induced analgesia in mice. Anesth Analg. 1995 May;80(5):944-8. [3]. Chipkin RE, et, al. Pharmacology of SCH 34826, an orally active enkephalinase inhibitor analgesic. J Pharmacol Exp Ther. 1988 Jun;245(3):829-38.

Reseñas

Review for SCH 32615

Average Rating: 5 ★★★★★ (Based on Reviews and 20 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SCH 32615

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.